GENMAB A/S/S (OTCMKTS:GMXAY) Shares Cross Above Fifty Day Moving Average – Here’s What Happened

GENMAB A/S/S (OTCMKTS:GMXAY) passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $29.29 and traded as high as $33.90. GENMAB A/S/S shares last traded at $33.75, with a volume of 3,086,697 shares.

GENMAB A/S/S Trading Down 1.8%

The firm’s fifty day moving average price is $29.29 and its 200-day moving average price is $27.97.

Hedge Funds Weigh In On GENMAB A/S/S

A hedge fund recently bought a new stake in GENMAB A/S/S stock. Madison Asset Management LLC purchased a new position in shares of GENMAB A/S/S (OTCMKTS:GMXAY) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.